Find out more about who we are, what we do and the people behind Epitopea.
Find out what makes us unique and the work we do with our revolutionary CryptoMapTM platform.
All the latest company news, press releases and updates from Epitopea.
Contact

News & Events:

Revealing the true targets for next generation immunotherapies.
Learn More

European Biotechnology Magazine

Date: June 11, 2026 |
RNA medicine enters its ­ second act By Joachim Eeckhout, June 11, 2026 INNOVATION The COVID-19 pandemic trans- formed RNA technologies into one of the […]
Read More

Drug Discovery World

Date: April 24, 2026 |
MHRA approves clinical trial for ovarian cancer therapy  By Bruno Quinney, April 24, 2026 The UK’s Medicines and Healthcare products Regulatory […]
Read More

European Biotechnology Magazine

Date: April 23, 2026 |
Epitopea wins UK approval for therapeutic vaccine trial By Uta Mommert, April 23, 2026 CryptiVax-1001 is set to enter first-in-human testing […]
Read More

Manufacturing Chemist

Date: April 23, 2026 |
Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer  The company has received regulatory approval from the […]
Read More

Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer

Date: April 23, 2026 |
Appoints Leading Oncologist Professor Susana Banerjee of The Royal Marsden as Chief Investigator CAMBRIDGE, UK and MONTREAL, CANADA, 23 April 2026 – Epitopea, a transatlantic biotech developing off-the-shelf, durable, RNA-based cancer immunotherapies, today announced that it has received […]
Read More

Epitopea Strengthens Scientific Advisory Board with Appointment of Leading Authority in Cancer, Lisa Butterfield

Date: April 13, 2026 |
CAMBRIDGE, UK and MONTREAL, CANADA, 13 April 2026 — Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies […]
Read More

Genetic Engineering News

Date: April 1, 2026 |
Engineering Biology to Fight Cancer Solid tumors are heterogeneous with an immunosuppressive tumor microenvironment, but that is not slowing the […]
Read More

Epitopea Strengthens Scientific Advisory Board with Appointment of Four World Renowned Experts in Cancer Immunology and Immunotherapy

Date: September 18, 2025 |
CAMBRIDGE, UK and MONTREAL, CANADA, 18 September 2025 – Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, […]
Read More

Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic

Date: July 10, 2025 |
CAMBRIDGE, UK and MONTREAL, CANADA, 10 July 2025 – Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, […]
Read More

Epitopea Announces Nature Cancer Paper on Novel Immunotherapy Targets in Melanoma and NSCLC

Date: May 27, 2025 |
Further Validates CryptigensTM as Actionable Targets for Cancer Immunotherapy Montreal, Quebec, & Cambridge, UK, 27 May 2025 – Epitopea, a […]
Read More
1 2 3
Revealing Novel Targets For Next Generation Immunotherapies
© 2022 – 2026 Epitopea Ltd | All Rights Reserved
Created by FDM Digital